Just got out of a meeting and saw the news. This is a home run!
A couple of observations about the data:
1. The alpha was exactly 0.043 as I calculated from the 22% risk reduction that DNDN announced that they needed to win.
2. The risk reduction of 22.5% is much better than Taxotere 21% and in line with what the various models of IMPACT implied.
3. The median benefit of 4.1 months is great! It was much larger than my model predicted. Just goes to say it's hard to get everything right. But this was the hardest statistics to estimate due to its noisy nature.
But those are just details. This is the day that we have been hoping for. The dawn of a new era in treating cancers.
There is no question at this point that Provenge will be the standard of care for PC once it is approved. For the sake of all patients, let's hope that the FDA will be able to move quickly to approve Provenge soon.
Congratulations to all of us who stuck it out with Dendreon over the years!
